Longboard Pharmaceuticals (NASDAQ:LBPH – Get Rating)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $25.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 482.75% from the stock’s current price.
Several other research analysts have also recently weighed in on the company. Wedbush restated an “outperform” rating on shares of Longboard Pharmaceuticals in a report on Friday, March 3rd. Citigroup lowered their target price on Longboard Pharmaceuticals from $24.00 to $17.00 and set a “buy” rating on the stock in a report on Sunday, March 5th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Longboard Pharmaceuticals currently has an average rating of “Buy” and an average target price of $19.33.
Longboard Pharmaceuticals Trading Down 10.4 %
NASDAQ:LBPH opened at $4.29 on Wednesday. The firm has a market cap of $98.54 million, a P/E ratio of -1.67 and a beta of 1.17. The stock has a 50 day moving average of $5.06 and a two-hundred day moving average of $4.38. Longboard Pharmaceuticals has a 12 month low of $2.70 and a 12 month high of $6.47.
Institutional Inflows and Outflows
About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies.
- Get a free copy of the StockNews.com research report on Longboard Pharmaceuticals (LBPH)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Longboard Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longboard Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.